X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.onclive.com/view/subcutaneous-trastuzumab-proves-safe-and-tolerable-in-her2-metastatic-breast-cancer
https://finance.yahoo.com/news/mercks-keytruda-combo-therapy-hits-195037284.html
https://www.centerforbiosimilars.com/view/long-term-phase-3-results-show-similar-efficacy-cardiac-safety-of-sb3-vs-herceptin
https://seekingalpha.com/news/3766692-bristol-myers-squibb-posts-encouraging-data-from-late-stage-opdivo-lung-cancer-trial
https://endpts.com/an-allergan-psychiatric-drug-failed-late-stage-depression-studies-but-abbvie-is-going-for-approval-anyway/
https://www.fiercebiotech.com/biotech/esmo-zymeworks-lays-down-marker-fight-to-unseat-herceptin
https://www.fiercepharma.com/pharma/while-there-short-term-pain-expect-long-term-gain-for-glaxosmithkline-s-shingrix-analyst
https://www.fiercepharma.com/marketing/macrogenics-her2-drug-scores-fda-breast-cancer-nod-herceptin-topping-data
http://www.pharmafile.com/news/556754/china-approves-its-first-biosimilar-roches-herceptin-her2-cancers
https://www.bigmoleculewatch.com/2020/07/07/breaking-news-genentech-and-amgen-settle-herceptin-and-avastin-biosimilar-disputes/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+GoodwinProcter-BigMoleculeWatchBlog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.raps.org/news-and-articles/news-articles/2020/7/fda-approvals-roundup-fintepla-dojolvi-phesgo
https://www.fiercepharma.com/pharma/roche-wards-off-herceptin-copycats-new-easy-to-use-perjeta-combo-product
https://www.prnewswire.com/news-releases/clinical-data-of-avifavir-to-become-available-to-international-partners-301085137.html
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/73443r-eng.php
https://www.fiercepharma.com/pharma/seattle-genetics-breaks-into-breast-cancer-new-approval-tukysa
https://www.biopharmadive.com/news/merck-samsung-herceptin-biosimilar-us-launch/576101/
https://www.bigmoleculewatch.com/2020/04/01/russian-pharma-company-biocad-obtains-european-certification-for-biosimilars-to-treat-cancer/
https://www.raps.org/news-and-articles/news-articles/2019/12/us-biosimilar-launches-about-to-turn-a-corner
https://www.prnewswire.com/news-releases/halozyme-announces-fda-has-accepted-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-using-enhanze-technology-301010295.html
https://www.biopharmadive.com/news/pfizer-hits-its-biosimilar-stride/571136/
http://www.pmlive.com/pharma_news/ema_backs_adjuvant_use_of_roches_breast_cancer_adc_kadcyla_1320584
https://www.fiercepharma.com/pharma/roche-under-fire-again-mylan-launches-herceptin-copycat-latest-blow-to-blockbuster-trio
https://www.fiercebiotech.com/biotech/seattle-genetics-breast-cancer-drug-hits-mark-pivotal-trial
https://www.fiercepharma.com/pharma/u-s-biosimilars-only-scratched-roche-s-cancer-blockbusters
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
https://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/
http://www.pmlive.com/pharma_news/roche_preps_filings_for_herceptinperjeta_combination_1301521
https://www.fiercepharma.com/pharma/roche-s-tecentriq-a-european-hot-streak-bags-two-new-lung-cancer-approvals
https://www.fiercepharma.com/pharma/genentech-to-settle-biosimilar-trade-secret-theft-suit-taiwan-s-jhl
https://www.thepharmaletter.com/in-brief/brief-chugai-seeks-new-kadcyla-indication-in-japan
https://endpts.com/the-top-10-franchise-drugs-in-biopharma-history-will-earn-a-total-of-1-4t-trillion-by-2024-what-does-that-tell-us/
https://www.fiercepharma.com/pharma/herceptin-drops-contracting-ahead-u-s-biosim-but-roche-raises-outlook-anyway
https://www.biospace.com/article/unum-plunges-after-fda-places-another-clinical-hold-on-company-asset/
http://www.pharmatimes.com/news/mundipharma_picks_up_rights_to_herceptin_biosimilar_tuznue_1293126
https://in.reuters.com/article/us-pfizer-fda/pfizers-avastin-biosimilar-wins-fda-approval-idINKCN1TT1Q9
https://endpts.com/chi-med-cuts-surufatinib-phiii-short-fda-greenlights-herceptin-copycat-from-amgen-allergan/
https://www.raps.org/news-and-articles/news-articles/2019/6/fda-approves-20th-biosimilar-5th-for-roches-herc
https://www.fiercepharma.com/pharma/roche-touts-phase-2-gazyva-data-lupus-nephritis-same-day-as-new-approval
https://www.fiercepharma.com/pharma/roche-snags-fda-approval-for-polivy-combo-certain-dlbcl-patients
https://www.biosimilardevelopment.com/doc/pfizer-launch-several-drugs-despite-generic-headwinds-0001
https://www.business-standard.com/article/companies/biocon-and-mylan-get-canadian-nod-for-biosimilar-cancer-drug-ogivri-119052201516_1.html
https://www.fiercepharma.com/marketing/puma-biotech-s-nerlynx-suffers-a-terrible-quarter-what-gives
https://www.fiercepharma.com/pharma/roche-genentech-s-ocrevus-continues-winning-streak-after-nice-flip-flops-initial-guidance
Market Place
Share 
